Liquid Biopsy: Query the Body, Not a Sample
Our synthetic biomarkers are administered to patients and tailor-made to query the activity of key biological targets such as proteases – a class of enzymes that drive critical disease pathways. Synthetic biomarkers exploit the human body’s own proteases and in vivo trafficking to create perfectly refined and trackable markers of disease which are accurate, sensitive, specific and detectable in a simple noninvasive urine test. It’s the new frontier of liquid biopsy.
Biology-AI Convergence: Glympse Inside™
We are building a comprehensive database of real-time biological activity in the human body that drives insights to validate drug-target engagement, determine responders and non-responders, and drive earlier and stronger outcomes for patients. At the earliest stages, we can gain a glimpse into the stage and progression of important, complex diseases such as cancer, fibrosis, inflammation, and infections.
At the core of our product engine is the integration of sophisticated machine learning and artificial intelligence to develop predictive algorithms targeting all clinically-relevant proteases involved in human biology and physiology. All trained by our unique approach that captures real-time biology inside the body – Glympse Inside™.